Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DRALSERP vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Depletes monoamines (serotonin, norepinephrine, dopamine) from central and peripheral nerve terminals by binding to and inhibiting the vesicular monoamine transporter 2 (VMAT2), impairing storage and leading to enzymatic degradation.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension,Psychotic disorders (especially in patients intolerant to neuroleptics),Huntington's chorea
Hypertension
0.25 mg orally once daily; may increase by 0.25 mg every 2 weeks to a maximum of 1 mg daily in divided doses.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is 45 to 50 hours; clinically significant as drug accumulates with repeated dosing, requiring careful titration.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Primarily hepatic via CYP2D6, CYP1A2, and CYP3A4; active metabolite: reserpiline.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily hepatic metabolism to inactive metabolites; less than 1% excreted unchanged in urine; approximately 10% eliminated in feces.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Approximately 96% bound to plasma proteins, primarily albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Volume of distribution is approximately 200 L/kg; extensive tissue distribution, particularly to adipose tissue.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral bioavailability is 50% to 60% due to extensive first-pass metabolism.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
No specific adjustment required; use with caution in severe renal impairment.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), reduce dose by 50%.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended for use in pediatric patients.
Not established; avoid use in children.
Start at 0.125 mg orally once daily; titrate slowly to avoid excessive sedation and hypotension.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Risk of depression and suicidal ideation; contraindicated in patients with a history of depression, suicidal tendencies, or Parkinson's disease.
None
May cause severe depression, suicidal thoughts, and extrapyramidal symptoms; avoid in patients with history of peptic ulcer disease (increases gastric acid secretion); may cause nasal congestion, bradycardia, and hypotension; use caution during surgery due to increased vagal tone.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
History of depression or suicidal tendencies; active peptic ulcer disease; ulcerative colitis; patients receiving electroconvulsive therapy; concurrent MAO inhibitors; hypersensitivity.
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce, tap beer) as reserpine can potentiate pressor response. Limit caffeine intake. Taking with food may reduce GI upset.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Associated with increased risk of congenital malformations including cardiovascular and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal hypotension. Avoid throughout pregnancy.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Excreted into breast milk; M/P ratio approximately 0.5. Potential for adverse effects in the infant, including bradycardia and sedation. Not recommended during breastfeeding.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No established safe dose; contraindicated in pregnancy. Clearance may increase in second and third trimesters, but no dose adjustment recommended due to teratogenicity.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
DRALSERP (reserpine) is an older antihypertensive that depletes catecholamines. Monitor for depression, especially in elderly. Onset slow (2-3 weeks). Avoid in patients with history of peptic ulcer disease due to increased gastric acid secretion. Combine with thiazide diuretic if necessary but watch for enhanced hypotensive effect.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed, usually once daily. Full effect may take several weeks.,Avoid driving or operating heavy machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.,Report any symptoms of depression, such as persistent sadness, loss of interest, or changes in sleep or appetite.,This drug can cause nasal congestion, dry mouth, or weight gain. Notify your doctor if these are bothersome.,Avoid alcohol, as it may increase side effects like dizziness and drowsiness.,Do not use over-the-counter cold, allergy, or weight loss products without consulting your doctor, as they may interact.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DRALSERP vs ALDORIL 25, answered by our medical review team.
DRALSERP is a Antihypertensive that works by Depletes monoamines (serotonin, norepinephrine, dopamine) from central and peripheral nerve terminals by binding to and inhibiting the vesicular monoamine transporter 2 (VMAT2), impairing storage and leading to enzymatic degradation.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DRALSERP and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DRALSERP is: 0.25 mg orally once daily; may increase by 0.25 mg every 2 weeks to a maximum of 1 mg daily in divided doses.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DRALSERP and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DRALSERP is classified as Category C. First trimester: Associated with increased risk of congenital malformations including cardiovascular and neural tube defects. Second and third trimesters: Risk of fetal growth rest. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.